COMMANDS Trial: Dr. Zeidan Talks Luspatercept in MDS, Anemia

By Amer Zeidan, MBBS, MHS - Last Updated: January 13, 2025

Amer Zeidan, MBBS, of Yale Cancer Center, discussed the COMMANDS trial of frontline luspatercept in transfusion-dependent patients with lower-risk MDS and anemia at the 66th American Society of Hematology Annual Meeting & Exposition.

Advertisement

“A good number of patients achieved transition independence for extended periods of time,” Dr. Zeidan explained. “We also saw data being presented regarding the hemoglobin rise and how the quality of life of patients correlate when the hemoglobin goes above 10. The data suggests that starting with luspatercept as the first-line agent is clearly the standard of care right now in patients who are ring sideroblast [RS]–positive. In patients who are RS-negative, this is still being discussed.”

Advertisement
Advertisement
Advertisement